137 related articles for article (PubMed ID: 18497956)
21. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.
Kazi A; Sun J; Doi K; Sung SS; Takahashi Y; Yin H; Rodriguez JM; Becerril J; Berndt N; Hamilton AD; Wang HG; Sebti SM
J Biol Chem; 2011 Mar; 286(11):9382-92. PubMed ID: 21148306
[TBL] [Abstract][Full Text] [Related]
22. Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Perri F; Muto P; Argenone A; Ionna F; Longo F; Fulciniti F; Sandomenico F; Daponte A; Caponigro F
Oncology; 2013; 84(4):251-4. PubMed ID: 23428719
[TBL] [Abstract][Full Text] [Related]
23. Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro.
Chung WH; Sung BH; Kim SS; Rhim H; Kuh HJ
Int J Oncol; 2009 Jun; 34(6):1669-79. PubMed ID: 19424586
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor.
Miller AV; Hicks MA; Nakajima W; Richardson AC; Windle JJ; Harada H
PLoS One; 2013; 8(4):e60685. PubMed ID: 23577147
[TBL] [Abstract][Full Text] [Related]
25. Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
Schulze-Bergkamen H; Ehrenberg R; Hickmann L; Vick B; Urbanik T; Schimanski CC; Berger MR; Schad A; Weber A; Heeger S; Galle PR; Moehler M
World J Gastroenterol; 2008 Jun; 14(24):3829-40. PubMed ID: 18609706
[TBL] [Abstract][Full Text] [Related]
26. Additive growth inhibition after combined treatment of 2-methoxyestradiol and conventional chemotherapeutic agents in human pancreatic cancer cells.
Fotopoulou C; Baumunk D; Schmidt SC; Schumacher G
Anticancer Res; 2010 Nov; 30(11):4619-24. PubMed ID: 21115915
[TBL] [Abstract][Full Text] [Related]
27. Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Vermorken JB; Mesia R; Rivera F; Remenar E; Kawecki A; Rottey S; Erfan J; Zabolotnyy D; Kienzer HR; Cupissol D; Peyrade F; Benasso M; Vynnychenko I; De Raucourt D; Bokemeyer C; Schueler A; Amellal N; Hitt R
N Engl J Med; 2008 Sep; 359(11):1116-27. PubMed ID: 18784101
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of Cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene.
Kojima H; Iida M; Yaguchi Y; Suzuki R; Hayashi N; Moriyama H; Manome Y
Arch Otolaryngol Head Neck Surg; 2006 Jun; 132(6):682-5. PubMed ID: 16785416
[TBL] [Abstract][Full Text] [Related]
29. Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study.
Benasso M; Merlano M; Sanguineti G; Corvò R; Numico G; Ricci I; Pallestrini E; Santelli A; Vitale V; Marchetti G; Rosso R
Am J Clin Oncol; 2001 Dec; 24(6):618-22. PubMed ID: 11801767
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
Li C; Li R; Grandis JR; Johnson DE
Mol Cancer Ther; 2008 Jun; 7(6):1647-55. PubMed ID: 18566236
[TBL] [Abstract][Full Text] [Related]
31. Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells.
Wacheck V; Cejka D; Sieghart W; Losert D; Strommer S; Crevenna R; Monia BP; Selzer E
Cancer Biol Ther; 2006 Oct; 5(10):1348-54. PubMed ID: 16969094
[TBL] [Abstract][Full Text] [Related]
32. Association of anti-apoptotic Mcl-1L isoform expression with radioresistance of oral squamous carcinoma cells.
Palve VC; Teni TR
Radiat Oncol; 2012 Aug; 7():135. PubMed ID: 22873792
[TBL] [Abstract][Full Text] [Related]
33. The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil.
Masuda M; Toh S; Koike K; Kuratomi Y; Suzui M; Deguchi A; Komiyama S; Weinstein IB
Jpn J Cancer Res; 2002 Mar; 93(3):329-39. PubMed ID: 11927016
[TBL] [Abstract][Full Text] [Related]
34. Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells.
Banerjee S; Choi M; Aboukameel A; Wang Z; Mohammad M; Chen J; Yang D; Sarkar FH; Mohammad RM
Pancreas; 2010 Apr; 39(3):323-31. PubMed ID: 19823097
[TBL] [Abstract][Full Text] [Related]
35. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells.
Song L; Coppola D; Livingston S; Cress D; Haura EB
Cancer Biol Ther; 2005 Mar; 4(3):267-76. PubMed ID: 15753661
[TBL] [Abstract][Full Text] [Related]
36. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Herbst RS; Arquette M; Shin DM; Dicke K; Vokes EE; Azarnia N; Hong WK; Kies MS
J Clin Oncol; 2005 Aug; 23(24):5578-87. PubMed ID: 16009949
[TBL] [Abstract][Full Text] [Related]
37. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Licitra L; Mesia R; Rivera F; Remenár É; Hitt R; Erfán J; Rottey S; Kawecki A; Zabolotnyy D; Benasso M; Störkel S; Senger S; Stroh C; Vermorken JB
Ann Oncol; 2011 May; 22(5):1078-1087. PubMed ID: 21048039
[TBL] [Abstract][Full Text] [Related]
39. Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Machiels JP; Kaminsky MC; Keller U; Brümmendorf TH; Goddemeier T; Forssmann U; Delord JP
Invest New Drugs; 2013 Oct; 31(5):1207-16. PubMed ID: 23397499
[TBL] [Abstract][Full Text] [Related]
40. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
